左卡尼汀、重组人促红细胞生长素及铁剂联合治疗血液透析并发症的临床效果

Clinical Effect of Levocarnitine Recombinant Human Erythropoietin and Iron Combination Therapy in Treatment of Hemodialysis Complications

目的探讨左卡尼汀、重组人促红细胞生长素及铁剂联合治疗血液透析并发症的临床效果。方法将作者医院2011-02/2012-02月60例血液透析并发症患者按照随机数字法分为对照组与观察组,均给予重组人促红细胞生长素+铁剂,观察组另外还给予左卡尼汀,观察两组的临床治疗效果。结果观察组治疗后的胸闷、心悸、乏力、低血压症状均完全消失(P<0.05),且心肌收缩加强;对照组治疗后的胸闷、心悸、乏力、低血压症、心律失常较治疗前改善不明显(P>0.05)。两组治疗后临床症状与体征改善情况比较具有明显差异(P<0.05)。两组治疗后血红蛋白、红细胞比容、血清铁蛋白和转铁蛋白饱和度较治疗前有明显改善,且治疗后两组差异有统计学意义(P<0.05)。结论临床中对于血液透析并发症患者给予左卡尼汀、重组人促红细胞生长素及铁剂联合治疗效果显著,能够有效的改善患者的不良反应,并改善其心功能,值得临床中应用。

Objective To study the efficacy of levoearnitine, recombinant human erythropoietin and iron combina- tion therapy in the treatment of hemodialysis complications. Methods Sixty cases with complication of hemodialysis in our hospital from February 2011 to February 2012 were randomly divided into control group and observation group. The control group was treated with recombinant human erythropoietin and iron. The observation group was treated additional- ly with levocarnitine. The efficacy of the two groups was observed. Results The symptoms including tightness in the chest, palpitation, weakness, low blood pressure in the observation group after treatment completely disappeared （P〈~ 0. 05）, and myocardial contraction was strengthened. These symptoms and cardiac arrhythmia were not significantly im- proved in the control group after treatment （P^I）. 115）. The improvement of the clinical symptoms and signs after treat ment were significant different between two groups （P^0.05）. The hemoglobin, hematocrit, serum ferritin and transfer- rin saturation of the two groups were significantly improved than those before treatment and signifieantly different be- tween two groups after treatment （P%0. 05）. Conclusion In clinical practice, levocarnitine, recombinam human eryth- ropoietin and iron combination therapy has good treatment effect for patients with hemodialysis complications, can effectively improve the adverse reactions and improve cardiac function, which is worthy of clinical application.